Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94303


Purpose:

A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.


Criteria:

Inclusion Criteria: - Male 18 years of age or older - Has tumor tissue available for diagnostics - Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study - ECOG score of 0 or 1 Exclusion Criteria: - Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent) - Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed) - Known to be HIV positive - Myocardial infarction within one year prior to entering the study


NCT ID:

NCT00061126


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Stanford, California 94303
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.